Alkermes

Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alkermes reports robust Q4 earnings, eyes growth through innovative products

Alkermes demonstrated strong financial performance in Q4 2022, driven by the successful launch of LYBALVI and continued growth in key products.
The company's focus on expanding market access, enhancing product awareness, and strategic investments position it for future success and revenue growth.
Challenges in meeting revenue targets, managing profitability, and refining market strategies require careful navigation and proactive decision-making.
Opportunities in advancing product launches, expanding the pipeline, and leveraging scientific advancements offer avenues for sustained growth and market leadership.

Alkermes reports robust Q1 earnings, eyes global expansion and innovation

Alkermes delivered strong financial results in Q1 2023, driven by key proprietary products and strategic initiatives like the LYBALVI direct-to-consumer campaign.
While facing challenges such as commercial pressures and financial optimization queries, the company remains focused on growth and profitability.
Opportunities for international expansion, strategic investments, and innovative drug development position Alkermes for future success and value creation for shareholders.

Alkermes reports strong Q2 earnings, eyes growth through strategic initiatives

Alkermes' Q2 2023 Earnings Call reflects robust financial performance, strategic focus on key products, and ongoing investment in growth opportunities. Resolving arbitration, strong net income, and cash position underscore financial strength amidst operational challenges.

Alkermes posts solid Q3 results, plans neuroscience focus post-separation

Alkermes delivered strong Q3 results with revenue growth across key products and a focus on disciplined cost management post-separation.
The company showcased promising data for ALKS 2680 and outlined strategic priorities to drive future growth in the neuroscience sector.
While challenges like managing expenses and addressing safety concerns exist, opportunities in expanding product offerings and market access strategies are key for future success.
Investors should monitor Alkermes' progress in optimizing dosing profiles, mitigating adverse events, and achieving profitability targets amidst competitive pressures.

Alkermes reports stellar 2023 results, eyes transformative neuroscience advancements

Alkermes' strong financial performance in 2023 sets the stage for continued growth and innovation in 2024.
Key products like LYBALVI, ARISTADA, and VIVITROL demonstrated robust sales growth, underpinning the company's success.
Addressing challenges such as liver toxicity and visual disturbances will be crucial for sustaining growth and product development.
Opportunities in advancing neuroscience studies and capital allocation strategies position Alkermes for future success and value creation.

Alkermes reports strong Q1 earnings, eyes growth through product differentiation

Alkermes' Q1 performance reflects solid revenue growth and profitability, driven by key product successes.
While facing challenges such as expense management and market access, the company remains well-positioned.
Opportunities for growth lie in expanding prescriber base, accelerating revenue, and leveraging product strengths.
Overall, Alkermes demonstrates financial resilience and strategic focus on sustainable growth.

Alkermes (ALKS) reports robust Q2 earnings, focuses on growth strategies

Alkermes (ALKS) delivered strong revenue performance in Q2 2024, driven by proprietary product growth and effective expense management.
The company showcased resilience amidst revenue challenges and emphasized strategic initiatives for profitability and pipeline advancement.
While facing industry challenges, Alkermes remains poised for growth through innovation, market expansion, and operational efficiency.
Strategic focus on advancing key products, exploring growth opportunities, and prudent financial management underpin Alkermes' growth trajectory.

Alkermes excels in Q3 earnings, targets $200M EBITDA in 2025

Alkermes demonstrated strong sales performance in Q3 2024, with a strategic focus on profitability and cash flow for the future. While facing challenges in certain revenue streams, the company is poised to capitalize on growth opportunities and drive financial success in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

DUBLIN, July 21, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

Alkermes to Report Second Quarter 2021 Financial Results on July 28, 2021

Aptargroup

Pacer US Export Leaders ETF

ResMed

Standard Motor Products

Tempur Sealy International

Vanguard S&P Small-Cap 600 Growth ETF

As the craze for meme stocks fades away, investors should consider growth investing to generate big returns. Here are 7 growth stocks to buy today.

7 Growth Stocks to Buy As Meme Stock Mania Fades

DUBLIN, June 30, 2021 /PRNewswire/ --  Alkermes plc  (Nasdaq: ALKS) today announced the presentation of new health economics and outcomes research related to healthcare resource use (HRU) among veterans with alcohol dependence at the 2021 Research Society on Alcoholism (RSA) Scientific Meeting/International Society for Biomedical Research on Alcoholism (ISBRA) Conference, which took place virtually June 19-23, 2021. The company presented results from a retrospective, observational study using data from the Veterans Health Administration (VHA) database, which includes healthcare encounters, treatments and laboratory tests at VHA facilities.

Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence

DUBLIN, June 22, 2021 /PRNewswire/ -- Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), today announced former professional baseball player and World Series champion, CC Sabathia, as a spokesperson for the company's My Relationship with Alcohol campaign, which is designed to help raise awareness about the disease of alcohol dependence and encourage people who are rethinking their relationship with alcohol to reach out to their healthcare provider. The My Relationship with Alcohol website aims to help decrease the stigma surrounding alcohol dependence by providing disease state education resources, personal stories, an interactive questionnaire to help people assess their drinking patterns, a discussion guide that offers ideas on how to start a conversation with a healthcare provider about alcohol dependence and information about treating the disease.

Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign

Alpine Immune Sciences

Biogen isn't the only company whose shares should benefit from a breakthrough drug.

Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs

DUBLIN, June 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin), Alkermes' novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy. The data are being presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually June 4-8, 2021, and in an investor webcast presentation hosted by the company.

Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting

DUBLIN, June 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 10:30 a.m. ET (3:30 p.m.

Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference

The FDA approves Alkermes' (ALKS) Lybalvi for the treatment of adults with schizophrenia or bipolar I disorder. Shares up

Alkermes' (ALKS) Schizophrenia, Bipolar I Disorder Drug Approved

The FDA has approved Alkermes plc's (NASDAQ: ALKS) Lybalvi, a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity, for schizophrenia and bipolar I disorder. The approval comes as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.

Alkermes Shares Move Higher On FDA Approval Of Schizophrenia, Bipolar Med

DUBLIN, June 1, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved LYBALVI™ (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. LYBALVI is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity.

Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder

DUBLIN, May 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will host a webcast and conference call at 4:00 p.m. ET (9:00 p.m.

Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

Alkermes (ALKS) Up 3.6% Since Last Earnings Report: Can It Continue?

DUBLIN, May 20, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Emily Peterson Alva, to the company's Board of Directors ("Board"). Emily Peterson Alva is an experienced public company board member and a financial, strategic and business advisor to growth companies.

Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors

Biogen

Bristol-Myers

Blueprint Medicines

Myovant Sciences

Provention Bio Inc

Sanofi

Vertex Pharmaceuticals

Biotech stocks frequently make big moves on a single trial result or FDA ruling. These 8 drugmakers are worth watching amid important events on deck this summer.

8 Biotech Stocks With Major Catalysts on the Horizon

DUBLIN, May 13, 2021 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced that the company will begin accepting applications for its Alkermes Inspiration Grants® program beginning on May 20, 2021. Now in its fifth year, this competitive grants program will provide up to a total of $500,000 in grants to assist nonprofit organizations in their work to address the needs of people living with addiction, serious mental illness or cancer.

Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer

An agreement with an activist investor capped a busy month.

Why Shares of Alkermes Rose 18% Last Month

Heron Therapeutics

Keeping track of upcoming events is important.

Want to Make Money in Biotech? Do This First

DUBLIN, May 5, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the BofA Securities 2021 Healthcare Conference on Wednesday, May 12, 2021 at 2:45 p.m. ET (7:45 p.m.

Alkermes to Take Part in the BofA Securities 2021 Virtual Healthcare Conference

DUBLIN, May 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during Mental Health Awareness Month in May. The meetings, all held virtually, include: American Psychiatric Association (APA) Annual Meeting, May 1-3; International Society for Bipolar Disorders (ISBD) Annual Conference, May 13-15; International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, May 17-20.

Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month

DUBLIN, April 30, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has reached an agreement with Sarissa Capital Management LP ("Sarissa Capital"), a beneficial owner of approximately 5% of the company's outstanding ordinary shares, pursuant to which Sarissa Capital has the right to designate a director to the company's Board of Directors (the "Board"). This agreement follows constructive dialogue between the parties related to the company's strategic priorities and ongoing Board refreshment efforts.

Alkermes Announces Agreement with Sarissa Capital

Alkermes' (ALKS) earnings rise year over year in the first quarter of 2021. Revenues surpass estimates.

Alkermes' (ALKS) Q1 Earnings Rise Y/Y, Revenues Beat Estimates

Alkermes Plc (ALKS) CEO Richard Pops on Q1 2021 Results - Earnings Call Transcript

Alkermes (ALKS) delivered earnings and revenue surprises of 320.00% and 10.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Alkermes (ALKS) Q1 Earnings and Revenues Beat Estimates

Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 1000.00% year over year to $0.11, which beat the estimate of ($0.02).

Alkermes: Q1 Earnings Insights

DUBLIN, April 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually June 4-8, 2021. New data from the phase 1/2 ARTISTRY-1 clinical trial evaluating the tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA®) will be shared in a poster discussion session.

News for Alkermes Stock (ALKS)